Gene Delivery Technologies Market Report 2026
Global Outlook – By Mode (Biological, Chemical, Physical), By Method (Ex Vivo, In Vivo, In Vitro), By Application (Gene Therapy, Cell Therapy, Vaccines, Research) - Market Size, Trends, Strategies, and Forecast to 2030
Gene Delivery Technologies Market Overview
• Gene Delivery Technologies market size has reached to $4.29 billion in 2025 • Expected to grow to $8.46 billion in 2030 at a compound annual growth rate (CAGR) of 14.5% • Growth Driver: Surge In Gene And Cell Therapies Drives Momentum In The Gene Delivery Technologies Market • Market Trend: Enhancing Gene Delivery Proteoanalyzer For Rapid Protein Analysis • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.What Is Covered Under Gene Delivery Technologies Market?
Gene delivery technologies refer to methods that are used to introduce foreign genetic material, such as DNA or RNA, into cells, where the goal of gene delivery is to transfer the genetic material into the target cells. These technologies are commonly used in treating diseases or disorders caused by changed gene-like mutations or an inherited gene. The main gene delivery technologies mode types are biological, chemical, and physical. Biological refers to the use of living organisms or their products in the development and delivery of gene therapy products. The various methods are ex vivo, in vivo, and in vitro applied in gene therapy, cell therapy, vaccines, and research.
What Is The Gene Delivery Technologies Market Size and Share 2026?
The gene delivery technologies market size has grown rapidly in recent years. It will grow from $4.29 billion in 2025 to $4.92 billion in 2026 at a compound annual growth rate (CAGR) of 14.7%. The growth in the historic period can be attributed to growth in gene therapy research, development of viral vectors, academic research funding, use of electroporation techniques, vaccine development programs.What Is The Gene Delivery Technologies Market Growth Forecast?
The gene delivery technologies market size is expected to see rapid growth in the next few years. It will grow to $8.46 billion in 2030 at a compound annual growth rate (CAGR) of 14.5%. The growth in the forecast period can be attributed to expansion of gene therapy pipelines, innovation in delivery vectors, demand for safer delivery methods, growth in cell therapy applications, increased clinical trial activity. Major trends in the forecast period include rising use of viral and non-viral delivery systems, increased adoption in gene and cell therapy, expansion of lipid nanoparticle technologies, growing focus on targeted gene delivery, advancements in physical gene transfer methods.
Global Gene Delivery Technologies Market Segmentation
1) By Mode: Biological, Chemical, Physical 2) By Method: Ex Vivo, In Vivo, In Vitro 3) By Application: Gene Therapy, Cell Therapy, Vaccines, Research Subsegments: 1) By Biological: Viral Vectors, Bacterial Vectors, Lipid Nanoparticles 2) By Chemical: Cationic Lipids, Polymers, Chemical Transfection Agents 3) By Physical: Electroporation, Microinjection, Gene Gun, SonoporationWhat Is The Driver Of The Gene Delivery Technologies Market?
The increasing number of cell and gene therapies is expected to propel the growth of the gene delivery technologies market going forward. Cell and gene therapies refer to medical treatments that aim to cure or alleviate diseases by altering a patient's body's genetic and cellular makeup. The increasing number of cell and gene therapies is mainly driven by advancements in gene editing technologies, playing a critical role in developing and commercializing cell and gene therapies. For instance, in March 2025, according to the IQVIA, a US-based provider of advanced analytics, technology solutions, and contract research services, reported that the volume of new CAR T trial starts reached 199 in 2024, with gene therapy trial starts reaching 130; these figures were up by 54% and 65%, respectively. Therefore, increasing cell and gene therapies drives the gene delivery technologies industry.Key Players In The Global Gene Delivery Technologies Market
Major companies operating in the gene delivery technologies market are Thermo Fisher Scientific Inc., QIAGEN NV, Horizon Discovery Group Co, OriGene Technologies Inc., Oxford Biomedica Solutions LLC, SignaGen Laboratories LLC, Vectalys SAS, Takara Bio Inc., Bio-Rad Laboratories Inc., System Biosciences LLC, Promega Corporation, Catalent Inc., Pfizer Inc., Becton Dickinson and Company, Novartis AG, Intellia Therapeutics Inc., Editas Medicine Inc., CRISPR Therapeutics AG, Spark Therapeutics Inc., Bluebird Bio Inc., Sarepta Therapeutics Inc., Beam Therapeutics Inc., Arrowhead Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Moderna Inc., BioNTech SE, Translate Bio Inc., CureVac N.V., Lonza Group AG
This chart is for illustrative purposes; the full report includes a detailed competitor analysis and comprehensive overview of the top 10 companies in the market.
This chart maps companies by product innovation and brand strength, with bubble size indicating relative revenue, helping identify market leaders, challengers, and niche players. This is an illustrative chart; the full report provides a complete and accurate competitive analysis.
Explore how leading companies compare across key metrics in our report Get Report
Global Gene Delivery Technologies Market Trends and Insights
Major companies operating in gene delivery technologies are focused on developing advanced products, such as ProteoAnalyzer, to gain a competitive edge in the market. The proteoAnalyzer is an advanced automated system developed by Agilent Technologies for protein analysis, specifically utilizing parallel capillary electrophoresis (CE) technology. For instance, in July 2024, Agilent Technologies Inc., a US-based life sciences company, launched ProteoAnalyzer system. This innovative platform is designed for automated parallel capillary electrophoresis (CE), enabling rapid, high-resolution protein analysis with minimal sample consumption. This capability is particularly beneficial for researchers working with complex protein mixtures in pharmaceuticals, biopharma, and bioengineered food ingredients, facilitating faster discoveries and advancements in translational research. The system allows for detailed examination of protein mixtures, which is crucial for developing therapeutic proteins.What Are Latest Mergers And Acquisitions In The Gene Delivery Technologies Market?
In January 2024, Kyowa Kirin Co. Ltd., a Japan-based pharmaceutical company, acquired Orchard Therapeutics plc for an undisclosed amount. With this acquisition, Kyowa Kirin aims to enhance its gene therapy portfolio, leveraging Orchard Therapeutics' expertise in hematopoietic stem cell (HSC) gene therapies to address rare genetic diseases and expand patient access to life-changing treatments. Orchard Therapeutics plc is a UK-based biopharmaceutical company that specializing in gene therapy.
Regional Outlook
North America was the largest region in the gene delivery technologies market in 2025.Asia-Pacific is expected to be the fastest-growing region in the global gene delivery technologies market report during the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.Need data for a specific geography? Request Regional Data
What Defines the Gene Delivery Technologies Market?
The gene delivery technologies market consists of revenues earned by entities by providing services such as viral vector production, gene editing, gene therapy, and cell therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. Gene delivery technologies also include sales of viral and non-viral vectors, transfection reagents, and gene editing tools that are used in providing gene delivery. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.How is Market Value Defined and Measured?
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This chart presents market attractiveness based on a quantitative evaluation of growth, competition, strategic alignment, and risk, offering a clear view of opportunity areas for decision-making. This chart is for illustrative purposes; the full report contains the complete analysis.
This chart highlights the Total Addressable Market (TAM) by estimating the maximum revenue opportunity using an assumption-driven approach, supporting strategic planning and opportunity sizing across markets. The chart is illustrative; the full report provides a more comprehensive analysis.
Access full TAM calculations and growth projections in our report Get Report
What Key Data and Analysis Are Included in the Gene Delivery Technologies Market Report 2026?
The gene delivery technologies market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the gene delivery technologies industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.Gene Delivery Technologies Market Report Forecast Analysis
| Report Attribute | Details |
|---|---|
| Market Size Value In 2026 | $4.92 billion |
| Revenue Forecast In 2030 | $8.46 billion |
| Growth Rate | CAGR of 14.5% from 2026 to 2030 |
| Base Year For Estimation | 2025 |
| Actual Estimates/Historical Data | 2020-2025 |
| Forecast Period | 2026 - 2030 |
| Market Representation | Revenue in USD Billion and CAGR from 2026 to 2030 |
| Segments Covered | Mode, Method, Application |
| Regional Scope | Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa |
| Country Scope | The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain |
| Key Companies Profiled | Thermo Fisher Scientific Inc., QIAGEN NV, Horizon Discovery Group Co, OriGene Technologies Inc., Oxford Biomedica Solutions LLC, SignaGen Laboratories LLC, Vectalys SAS, Takara Bio Inc., Bio-Rad Laboratories Inc., System Biosciences LLC, Promega Corporation, Catalent Inc., Pfizer Inc., Becton Dickinson and Company, Novartis AG, Intellia Therapeutics Inc., Editas Medicine Inc., CRISPR Therapeutics AG, Spark Therapeutics Inc., Bluebird Bio Inc., Sarepta Therapeutics Inc., Beam Therapeutics Inc., Arrowhead Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Moderna Inc., BioNTech SE, Translate Bio Inc., CureVac N.V., Lonza Group AG |
| Customization Scope | Request for Customization |
| Pricing And Purchase Options | Explore Purchase Options |